.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
SYGMA 1 compared as-needed budesonide-formoterol, daily maintenance budesonide plus as-needed reliever, and as-needed terbutaline in patients with mild asthma. The trial showed that as-needed budesonide-formoterol provided better symptom control than terbutaline alone and substantially reduced the rate of severe exacerbations compared with the beta-agonist-only strategy. Its exacerbation protection was broadly similar to daily budesonide, while total inhaled glucocorticoid exposure was considerably lower. The study is important because it challenged the assumption that patients with mild asthma must use a fixed daily inhaled corticosteroid schedule to obtain meaningful protection from severe exacerbations. At the same time, as-needed therapy was not equivalent to maintenance budesonide for symptom control. For practicing HCPs, this distinction is critical: the appropriate reliever/controller strategy depends on the clinical phenotype, symptom pattern and goals of treatment. The findings fit the NAPCON allergy and airway track, particularly its emphasis on phenotyping and practical inhaler decisions. The study should be discussed alongside modern asthma strategy rather than used to justify intermittent treatment without an anti-inflammatory component.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
SYGMA 1 compared as-needed budesonide-formoterol, daily maintenance budesonide plus as-needed reliever, and as-needed terbutaline in patients with mild asthma. The trial showed that as-needed budesonide-formoterol provided better symptom control than terbutaline alone and substantially reduced the rate of severe exacerbations compared with the beta-agonist-only strategy. Its exacerbation protection was broadly similar to daily budesonide, while total inhaled glucocorticoid exposure was considerably lower. The study is important because it challenged the assumption that patients with mild asthma must use a fixed daily inhaled corticosteroid schedule to obtain meaningful protection from severe exacerbations. At the same time, as-needed therapy was not equivalent to maintenance budesonide for symptom control. For practicing HCPs, this distinction is critical: the appropriate reliever/controller strategy depends on the clinical phenotype, symptom pattern and goals of treatment. The findings fit the NAPCON allergy and airway track, particularly its emphasis on phenotyping and practical inhaler decisions. The study should be discussed alongside modern asthma strategy rather than used to justify intermittent treatment without an anti-inflammatory component.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
Yesterday
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
2 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
2 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
3 days back
